TSX:BHC (Bausch Health Companies)

About BHC

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.
  • Bausch Health Companies (TSX: BHC) Latest News

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Drops After Q3 Results Disappoint

    Troubles continue for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) as the company posts worse than expected results.

    Read more »

    The Motley Fool
    Investing

    Should You Buy Valeant Pharmaceuticals Intl Inc. After its 22% Plunge?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) took a huge hit in its latest earnings report, and the stock responded by dropping…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Should You Try to Catch This Falling Knife?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) just reminded investors that cheap stocks can get a lot cheaper very quickly.

    Read more »

    The Motley Fool
    Dividend Stocks

    3 Canadian Stocks to Buy in a Donald Trump World

    A Trump presidency is good news for TransCanada Corporation (TSX:TRP)(NYSE:TRP), Barrick Gold Corp. (TSX:ABX)(NYSE:ABX), and one other stock.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Is in Trouble Again: Down 25%

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a lottery ticket with huge upside and downside potential.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals International Inc. Q3 Earnings Preview: It’s Gonna Be Ugly

    What to expect from the market's most beaten-up stock, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) next Tuesday.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. in Talks to Sell $10 Billion Division: What Now?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) had big news on Tuesday. Investors need to be patient and wait.

    Read more »

    The Motley Fool
    Investing

    The Real Reason Why Bill Ackman Still Holds Valeant Pharmaceuticals Intl Inc.

    Valeant Pharmaceutical Intl Inc. (TSX:VRX)(NYSE:VRX) has fallen so much that there might be some value to be had. Bill Ackman…

    Read more »

    The Motley Fool
    Investing

    Why Valeant Pharmaceuticals Intl Inc. Is the Best Contrarian Pick for 2017

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a newly minted value stock, which offers an interesting entry point for long-term investors.…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Turnaround Candidate or Racing to the Bottom?

    Valent Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is making all of the right business decisions, but it may not be enough to…

    Read more »

    The Motley Fool
    Investing

    Concordia International Corp.: A Safe Buy?

    Concordia International Corp. (TSX:CXR)(NASDAQ:CXRX) is a risky, debt-ridden company that could grow quite handsomely if a series of steps are…

    Read more »

    The Motley Fool
    Investing

    Should You Buy Valeant Pharmaceuticals Intl Inc.?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a risky buy, even if it can get its debt under control--and that's a…

    Read more »